These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 20939743)

  • 1. Avanafil, a new rapid-onset phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction.
    Limin M; Johnsen N; Hellstrom WJ
    Expert Opin Investig Drugs; 2010 Nov; 19(11):1427-37. PubMed ID: 20939743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability.
    Wang R; Burnett AL; Heller WH; Omori K; Kotera J; Kikkawa K; Yee S; Day WW; DiDonato K; Peterson CA
    J Sex Med; 2012 Aug; 9(8):2122-9. PubMed ID: 22759639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Future prospects in the treatment of erectile dysfunction: focus on avanafil.
    Alwaal A; Al-Mannie R; Carrier S
    Drug Des Devel Ther; 2011; 5():435-43. PubMed ID: 22087063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Avanafil for erectile dysfunction.
    Kyle JA; Brown DA; Hill JK
    Ann Pharmacother; 2013 Oct; 47(10):1312-20. PubMed ID: 24259695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of avanafil for treating erectile dysfunction: results of a multicentre, randomized, double-blind, placebo-controlled trial.
    Zhao C; Kim SW; Yang DY; Kim JJ; Park NC; Lee SW; Paick JS; Ahn TY; Moon KH; Chung WS; Min KS; Suh JK; Hyun JS; Park K; Park JK
    BJU Int; 2012 Dec; 110(11):1801-6. PubMed ID: 22448738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Avanafil for the treatment of erectile dysfunction.
    Segal R; Burnett AL
    Drugs Today (Barc); 2012 Jan; 48(1):7-15. PubMed ID: 22384456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Avanafil for the treatment of erectile dysfunction.
    Zurawin JL; Stewart CA; Anaissie JE; Yafi FA; Hellstrom WJ
    Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1163-70. PubMed ID: 27416913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Avanafil (Stendra)--another PDE5 inhibitor for erectile dysfunction.
    Med Lett Drugs Ther; 2014 May; 56(1442):37-8. PubMed ID: 24818838
    [No Abstract]   [Full Text] [Related]  

  • 9. Avanafil - a further step to tailoring patient needs and expectations.
    Boeri L; Capogrosso P; Ventimiglia E; Serino A; La Croce G; Russo A; Damiano R; Montorsi F; Salonia A
    Expert Rev Clin Pharmacol; 2016 Sep; 9(9):1171-81. PubMed ID: 27232892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction.
    Kotera J; Mochida H; Inoue H; Noto T; Fujishige K; Sasaki T; Kobayashi T; Kojima K; Yee S; Yamada Y; Kikkawa K; Omori K
    J Urol; 2012 Aug; 188(2):668-74. PubMed ID: 22704456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PDE5 inhibitors: considerations for preference and long-term adherence.
    Smith WB; McCaslin IR; Gokce A; Mandava SH; Trost L; Hellstrom WJ
    Int J Clin Pract; 2013 Aug; 67(8):768-80. PubMed ID: 23869678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors.
    Bruzziches R; Francomano D; Gareri P; Lenzi A; Aversa A
    Expert Opin Pharmacother; 2013 Jul; 14(10):1333-44. PubMed ID: 23675780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of phosphodiesterase type 5 (PDE5) inhibitors.
    Wright PJ
    Int J Clin Pract; 2006 Aug; 60(8):967-75. PubMed ID: 16780568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Avanafil for treatment of erectile dysfunction: review of its potential.
    Burke RM; Evans JD
    Vasc Health Risk Manag; 2012; 8():517-23. PubMed ID: 22973106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction?
    Doggrell S
    Int J Impot Res; 2007; 19(3):281-95. PubMed ID: 17183346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of switching phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: results from the Erectile Dysfunction Observational Study.
    Hatzichristou D; Haro JM; Martin-Morales A; von Keitz A; Riley A; Bertsch J; Belger M; Wolka AM; Beardsworth A;
    Int J Clin Pract; 2007 Nov; 61(11):1850-62. PubMed ID: 17850306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphodiesterase 5 inhibitors for erectile dysfunction.
    Setter SM; Iltz JL; Fincham JE; Campbell RK; Baker DE
    Ann Pharmacother; 2005; 39(7-8):1286-95. PubMed ID: 15941818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A survey on the experience of 136 Italian urologists in the treatment of erectile dysfunction with PDE5 inhibitors and recommendations for the use of Avanafil in the clinical practice.
    Mirone V; Fusco F; Parazzini F; Zucchi A
    Arch Ital Urol Androl; 2016 Jul; 88(2):128-32. PubMed ID: 27377089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of erectile dysfunction course on its progress and efficacy of treatment with phosphodiesterase type 5 inhibitors.
    Liu DF; Jiang H; Hong K; Zhao LM; Tang WH; Ma LL
    Chin Med J (Engl); 2010 Nov; 123(22):3258-61. PubMed ID: 21163126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Avanafil for the treatment of erectile dysfunction. An updated review.
    Egui-Rojo MA; Moncada-Iribarren I; Carballido-Rodríguez J; Martínez-Salamanca JI
    Arch Esp Urol; 2014 Dec; 67(10):839-47. PubMed ID: 25582903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.